October 2022 "The prefrontal cortex (PFC) is a hub for cognitive control, and dopamine profoundly influences We find that PFC astrocytes express receptors for dopamine but are unresponsive through the Gs/Gi-cAMP Instead, fast calcium signals in PFC astrocytes are time locked to dopamine release and are mediated by α1-adrenergic receptors both ex vivo and in vivo. active players in dopaminergic signaling in the PFC, contributing to PFC function though neuromodulator receptor

August 2022 Dopamine D 1 receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, A major pan-receptor focus has been to identify GPCR-selective ligands that have bias in G protein-dependent exploded during the past two decades, it is only recently that highly β-arrestin biased ligands for the dopamine D1 receptor were reported.

Alterations in the expression and/or activity of brain G-protein-coupled receptors (GPCRs) such as dopamine D1R, D2LR, D3R, and D4R, vasopressin V1AR, and serotonin 5-HT1AR are noted in various neurodegenerative explored the functional role of kurarinone, an abundant lavandulated flavonoid in Sophora flavescens , on dopamine receptor subtypes, V1AR, 5-HT1AR, and hMAOs.

The bioactive lysophospholipid sphingosine-1-phosphate (S1P) acts via five different subtypes of S1P receptors Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor In this article, we describe a 2.2 Å resolution room temperature crystal structure of the human S1P5 receptor demonstrates a unique ligand-binding mode, involving an allosteric sub-pocket, which clarifies the receptor

influence predominantly arises via engagement with the principal two G-protein-coupled cannabinoid receptors Earlier publications have indicated that expression of CB1 receptor mRNA and protein has been recognized The part played by CB1 receptor activation or inhibition with respect to these functions and relevant This can be deduced from the qRT-PCR assays; triggering CB1 receptors amplifies both NR4A1 and NR4A3 The impact of ACEA is inhibited by the selective CB1 receptor antagonist, rimonabant.

A role for BET proteins in regulating basal, dopamine-induced and cAMP/PKA-dependent transcription in striatal neurons The activity of striatal medium-spiny projection neurons is regulated by D1 and D2 dopamine receptors. The D1 receptor (D1R) is a Gαs/olf-coupled GPCR which activates a cAMP/PKA/DARPP-32 signalling cascade We further found that cAMP/PKA signalling promotes Brd4 recruitment to dopamine-induced genes in striatal

September 2022 Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits "Although the cannabinoid type-2 receptor (CB2) is highly expressed in the immune system effects of CB2 receptor activation, make this receptor an intriguing target for treating schizophrenia , a disease where novel interventions that move beyond dopamine receptor antagonists are desperately , has greatly advanced our understanding of this receptor.

September 2022 "Serotonin receptor 5-HT2A and tropomyosin receptor kinase B (TrkB) strongly contribute decreased TrkB autophosphorylation, preventing its activation with agonist 7,8-DHF, even with low 5-HT2A receptor A blockade of 5-HT2A receptor with the preferential antagonist ketanserin prevented the receptor-mediated Our data reveal the functional role of 5-HT2A–TrkB receptor heterodimerization and suggest that the regulated

October 2022 "Protease activated receptors (PARs) are among the first receptors shown to transactivate other receptors: noticeably, these interactions are not limited to members of the same family, but involve receptors as diverse as receptor kinases, prostanoid receptors, purinergic receptors and ionic channels the evidence for PAR interactions with members of their own family, as well as with other types of receptors pathological relevance of these interactions, since this additional level of molecular cross-talk between receptors

all these situations, chemokines interact with seven-transmembrane chemokine-type G protein-coupled receptors (chemokine receptors, CKRs) and glycosaminoglycans (GAGs) to regulate the movement of leukocytes throughout In humans there are approximately 45 chemokines, 19 chemotactic or G-protein coupled chemokine receptors (CKRs) that signal via Gαi and 4 official atypical chemokine receptors (ACKRs) which engage in ligand CCR2 is an example of a dual-function receptor that directly regulates both cell migration and scavenging

October 2022 "The canonical model for G protein-coupled receptors (GPCRs) activation assumes that stimulation In this model, GPCR signaling is turned-off by receptor phosphorylation via GPCR kinases (GRKs) and subsequent recruitment of β-arrestins, resulting in receptor internalization into endosomes. Internalized receptors can then recycle back to the cell surface or be trafficked to lysosomes for degradation This is the case for the parathyroid hormone (PTH) type 1 receptor (PTHR), which engages on sustained

about State transitions of coupled Gi-protein: Insights into internal water channel dynamics within dopamine receptor D3 from in silico submolecular analyses Joseph Crecelius , Adriano Marchese , et al. for their as a novel desensitization mechanism for G protein-coupled receptors, illustrated by dopamine D2-like within dopamine receptor D3 from in silico submolecular analyses GPCRs in Cardiology, Endocrinology, Gαolf expression and signaling in murine brain tissue Regulator of G protein signaling 6 (RGS6) in dopamine

October 2022 "Melanocortin 3 receptor (MC3R) is a G-protein coupled receptor (GPCR) that is defined

October 2022 "Type 2 bradykinin receptor (B2R) is an essential G protein-coupled receptor (GPCR) that

August 2022 "As the only member of the CX3C chemokine receptor subfamily, CX3CR1 binds to its sole endogenous Thus, our data deepen the understanding of cholesterol modulation in GPCR (G protein-coupled receptor

C5a is established to interact with a set of genomically related transmembrane receptors, like C5aR1 The C5aR1 is a classical G-protein-coupled receptor (GPCR), whereas C5aR2 is a nonclassical GPCR that

Chemokine receptors (CKRs) belong to a subfamily of G-protein-coupled receptors (GPCRs) and play a crucial complexes and revealing the diverse and multifaceted nature of the chemokine receptor system. Data Bank (PDB) which reveal common structural features, such as the presence of seven transmembrane domains located below the 7TM cavity in the middle of the transmembrane region, and the N7.49P7.50xxY7.53 and D3.49R3.50Y3.51 In class A GPCRs, the inactive conformation is stabilized by the inactive configuration of the D3.49R3.50Y3.51motif

performed both at Sosei Heptares and Glasgow University characterizing the role of the muscarinic M1 receptor

October 2022 Intermolecular Interactions in G Protein-Coupled Receptor Allosteric Sites at the Membrane Quantum Chemical Calculations "Allosteric modulators are called promising candidates in G protein-coupled receptor (GPCR) drug development by displaying subtype selectivity and more specific receptor modulation. Among the allosteric sites known to date, cavities at the receptor-lipid interface represent an uncharacteristic In this work, we analyze interactions in the allosteric sites of the PAR2, C5aR1, and GCGR receptors

October 2022 "Recently determined structures of class C G protein-coupled receptors (GPCRs) revealed this work, molecular docking screens for allosteric modulators targeting the metabotropic glutamate receptor The mGlu5 receptor is activated by the main excitatory neurotransmitter of the nervous central system , L-glutamate, and mGlu5 receptor activity can be allosterically modulated by negative or positive allosteric The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases

The chemokine receptor system is implicated in a wide range of inflammatory, autoimmune and infectious The involvement of chemokines and their receptors in several aspects of cancer biology, represents a Furthermore, both chemokines and receptors can homo- and hetero-oligomerize, impacting receptor/ligand-binding and are also too small to be engaged by antibodies, which can only interact with the extracellular domain of the receptor ((Zimmermann, Conkright, and Rothenberg 1999).

For example, dimerization has been shown to affect signaling pathways in class A dopamine receptors like D1/D2 and D1/D3, which exhibit distinct pharmacological profiles in their dimeric form compared to their This dimerization allows the N-terminal activation domain of the receptor to repeatedly engage and disengage Additionally, the dimeric state allows rotational movement of the receptor's extracellular domain (ECD Perreault, M.L., et al., Heteromeric dopamine receptor signaling complexes: emerging neurobiology and

September 2022 "Introduction Protease activated receptors 1 (PAR1) and 4 (PAR4) agonists are used to

Prokineticins (PKs) exert their biological functions through the activation of the G protein-coupled receptors (GPCRs) prokineticin receptor 1 and 2 (PKR1, 2), and mutations in the PK2 and PKR2 genes are involved We also show that the N-terminal region of anosmin 1, capable of binding to the PK2-binding domain of 1 (FnIII.1) suggest the cysteine-rich (CR) and the FnIII.1 domains could assist the WAP domain both in the binding to PKR2 and in the modulation of the activation of the receptor by PK2.

G protein-coupled receptor interactions and modification of signalling involving the ghrelin receptor , GHSR1a The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH) (GPCRs), including dopamine D1 and D2, serotonin 2C, orexin, oxytocin and melanocortin 3 receptors ( In all cases, the receptor interaction changes downstream signalling and the responses to receptor agonists

August 2022 "Background: Activation of signaling effectors by G-protein coupled receptors (GPCRs) depends

Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets The adenosine A1 and A2A receptors are expressed in the human brain and have a proposed involvement in Targeting these receptors preclinically can mitigate pathogenic β-amyloid and tau neurotoxicity whilst accessible summary of the literature on Alzheimer's disease and the therapeutic potential of A1 and A2A receptors Although there are no available medicines targeting these receptors approved for treating dementia, we

Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets The adenosine A1 and A2A receptors are expressed in the human brain and have a proposed involvement in Targeting these receptors preclinically can mitigate pathogenic β-amyloid and tau neurotoxicity whilst accessible summary of the literature on Alzheimer's disease and the therapeutic potential of A1 and A2A receptors Although there are no available medicines targeting these receptors approved for treating dementia, we